Novo Nordisk A/S (NYSE:NVO) Issues Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings results on Tuesday. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.19, Zacks reports. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.

Novo Nordisk A/S Trading Down 6.4%

Shares of Novo Nordisk A/S stock traded down $3.02 during trading on Tuesday, hitting $44.07. The stock had a trading volume of 17,950,368 shares, compared to its average volume of 17,988,822. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The stock has a 50 day simple moving average of $46.96 and a 200 day simple moving average of $45.32. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $196.79 billion, a PE ratio of 10.38, a P/E/G ratio of 4.30 and a beta of 0.76.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Finally, Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Five investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported progress on its previously announced DKK 15 billion share-repurchase program. Continued buybacks can support earnings per share and signal management confidence in the stock’s valuation. Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme
• Positive Sentiment: The company is partnering with H1 to expand AI-driven clinical development, potentially improving trial design, execution and data analysis. The initiative is strategically positive but is unlikely to materially affect near-term revenue. H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development
• Neutral Sentiment: Chief Executive Mike Doustdar is emphasizing risk-taking and the potential of Novo Nordisk’s weight-loss pill and newer medicines. The strategy could help the company regain momentum against Eli Lilly, but investors will want evidence of successful launches and stronger growth. Arrogance kills: Novo chief injects risk-taking into Ozempic maker
• Negative Sentiment: Novo Nordisk’s experimental heart drug ziltivekimab failed to meet the primary endpoint in the Phase 3 ZEUS trial. The setback undermines hopes of diversifying beyond GLP-1 therapies and has increased scrutiny of the company’s development pipeline. Novo Nordisk shares in hot water after disappointing trial
• Negative Sentiment: Citi maintained a Neutral rating, saying the selloff after the trial failure may have been excessive but citing persistent risks from obesity-drug pricing pressure, slowing injectable GLP-1 momentum and intense competition from Eli Lilly. Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVO. Boston Partners acquired a new stake in Novo Nordisk A/S in the third quarter valued at approximately $310,199,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Novo Nordisk A/S by 99.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares during the last quarter. Voloridge Investment Management LLC boosted its holdings in Novo Nordisk A/S by 851.6% in the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after purchasing an additional 4,302,126 shares in the last quarter. Bank of Montreal Can boosted its holdings in Novo Nordisk A/S by 138.9% in the fourth quarter. Bank of Montreal Can now owns 2,525,827 shares of the company’s stock worth $128,514,000 after purchasing an additional 1,468,409 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new position in Novo Nordisk A/S during the fourth quarter worth $59,882,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.